ONO-4538 Phase I Study in Patients With Solid Tumor
ONO-4538 Multicenter, Open-label, Uncontrolled, Phase I Study in Solid Tumor
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
-
Seoul, Korea, Republic of
- Seoul Clinical Site 101
-
Seoul, Korea, Republic of
- Seoul Clinical Site 102
-
Seoul, Korea, Republic of
- Seoul Clinical Site 103
-
Seoul, Korea, Republic of
- Seoul Clinical Site 104
-
-
Gyeonggi-do
-
Seongnam-si, Gyeonggi-do, Korea, Republic of
- Seongnam-si Clinical Site 105
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Male or female ≥ 20 years of age
- Histologically or cytologically confirmed solid tumor
- Patients with advanced or recurrent solid tumors who are refractory or intolerant to standard therapy or for whom no appropriate treatment is available
- ECOG Performance Status is 0 to 1
Exclusion Criteria:
- Current or prior severe hypersensitivity to another antibody product
- Multiple primary cancers
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Sequential Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: ONO-4538 1mg/kg
ONO-4538 water-soluble injection, 100 mg/vial, 1mg/kg, single dose
|
|
|
Experimental: ONO-4538 3mg/kg
ONO-4538 water-soluble injection, 100 mg/vial, 3mg/kg, single dose
|
|
|
Experimental: ONO-4538 10mg/kg
ONO-4538 water-soluble injection, 100 mg/vial, 10mg/kg, single dose
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
PK Outcome: Cmax of ONO-4538
Time Frame: 3 weeks: from the start of administration to the end of treatment phase. Actual blood sampling points are pre-dose, 1hr, 3hr, 9hr, 25hr, 49hr, 73hr, 169hr, 337hr, and 504hr.
|
Cmax was the maximum serum concentration of ONO-4538 after the single administration.
|
3 weeks: from the start of administration to the end of treatment phase. Actual blood sampling points are pre-dose, 1hr, 3hr, 9hr, 25hr, 49hr, 73hr, 169hr, 337hr, and 504hr.
|
|
PK Outcome: Tmax of ONO-4538
Time Frame: 3 weeks: from the start of administration to the end of treatment phase. Actual blood sampling points are pre-dose, 1hr, 3hr, 9hr, 25hr, 49hr, 73hr, 169hr, 337hr, and 504hr.
|
Tmax was the time to reach the Cmax.
|
3 weeks: from the start of administration to the end of treatment phase. Actual blood sampling points are pre-dose, 1hr, 3hr, 9hr, 25hr, 49hr, 73hr, 169hr, 337hr, and 504hr.
|
|
AUC21day
Time Frame: 3 weeks: from the start of administration to the end of treatment phase. Actual blood sampling points are pre-dose, 1hr, 3hr, 9hr, 25hr, 49hr, 73hr, 169hr, 337hr, and 504hr.
|
AUC21day was the area under serum concentration-time curve of ONO-4538 from day 0 to day 21 (last measurement).
|
3 weeks: from the start of administration to the end of treatment phase. Actual blood sampling points are pre-dose, 1hr, 3hr, 9hr, 25hr, 49hr, 73hr, 169hr, 337hr, and 504hr.
|
|
AUCinf
Time Frame: 3 weeks: from the start of administration to the end of treatment phase. Actual blood sampling points are pre-dose, 1hr, 3hr, 9hr, 25hr, 49hr, 73hr, 169hr, 337hr, and 504hr.
|
AUCinf was the area under serum concentration-time curve of ONO-4538 extrapolated to infinity.
|
3 weeks: from the start of administration to the end of treatment phase. Actual blood sampling points are pre-dose, 1hr, 3hr, 9hr, 25hr, 49hr, 73hr, 169hr, 337hr, and 504hr.
|
|
T1/2
Time Frame: 3 weeks: from the start of administration to the end of treatment phase. Actual blood sampling points are pre-dose, 1hr, 3hr, 9hr, 25hr, 49hr, 73hr, 169hr, 337hr, and 504hr.
|
T1/2 was the elimination half-life of serum concentration of ONO-4538.
|
3 weeks: from the start of administration to the end of treatment phase. Actual blood sampling points are pre-dose, 1hr, 3hr, 9hr, 25hr, 49hr, 73hr, 169hr, 337hr, and 504hr.
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Safety Outcome: The Number of Subjects With Overall Adverse Events
Time Frame: 3 weeks: from the start of administration to the end of treatment phase.
|
Adverse Events (AEs) were analyzed based on treatment emergent AEs (TEAEs), defined as any event not present prior to initiation of investigational product that first appeared following exposure to investigational product or any event already present that worsened relative to the pre-treatment state following exposure to investigational product.
|
3 weeks: from the start of administration to the end of treatment phase.
|
|
Safety Outcome: The Number of Deaths
Time Frame: 3 weeks: from the start of administration to the end of treatment phase.
|
Number of subjects with TEAEs leading to death.
|
3 weeks: from the start of administration to the end of treatment phase.
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Study Director: Mitsunobu Tanimoto, Ono Pharmaceutical Co. Ltd
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimated)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- ONO-4538-13
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.